Aiming to be a good flu prevention partner

Aiming to be a good flu prevention partner

This week marks National Influenza Vaccination Week and, today, the US Centers for Disease Control and Prevention (CDC) is hosting a Tweet chat from 1-2 PM EST (#NIVW2014) to highlight the importance of continuing flu immunization through the holiday season and beyond, especially for people at high risk of developing the flu or flu-related complications.  Peak flu season on average starts about now and lasts through February.

Read More

2014 IMPACT Award winners - Philadelphia

2014 IMPACT Award winners - Philadelphia

For nearly 20 years, we've honored outstanding nonprofit organizations for their work on building healthy communities in and around our campuses in Durham, NC and Philadelphia, PA through the GSK IMPACT Awards. This past Tuesday, December 2, we hosted the 2014 IMPACT Award ceremony for the Philadelphia winners and awarded $40,000 to nine local nonprofits. These winners address pressing community health challenges, including helping kids succeed in school, improving access to affordable housing, and increasing healthy eating. 

Read More

The $10,000 Challenge – 1 day 1 idea

The $10,000 Challenge – 1 day 1 idea

Each year, GSK supports outstanding local nonprofit organizations for their work building healthier communities in and around our campuses in Durham, NC and Philadelphia, PA. We do this through the GSK IMPACT Awards, which come with $40,000 for each winning organization to continue their meaningful work.

These organizations truly know how to build a healthier community, so we thought: heck, wouldn't it be fascinating to not just recognize the winners for what they have already achieved, but also explore what still can be done going forward? So today we launch the “$10,000 Challenge” and invited the winners to propose what they would do with an additional $10,000.

Read More

Partnering with Pharma: Who Knows Where It Will Lead?

Partnering with Pharma: Who Knows Where It Will Lead?

I have been studying proteins for 20 years with the contributions and participation of students, post-doctoral fellows and research scientists from my lab at the University of North Carolina at Chapel Hill. We principally study how proteins use information entering cells to control their movement relative to other cells. It is very basic research. So how, you might ask, did I find myself working with one of the largest pharmaceutical companies to develop drugs to treat skin cancer? It turns out that the proteins we study are abnormally active in the majority of skin cancers and I convinced GSK that these proteins would make great drug targets to treat this disease. 

Read More

2014 IMPACT Award winners - North Carolina

2014 IMPACT Award winners - North Carolina

For nearly 20 years, we've honored outstanding nonprofit organizations for their work on building healthy communities in and around our campuses in Durham, NC and Philadelphia, PA through the GSK IMPACT Awards. This past Wednesday, November 18, we hosted the 2014 IMPACT Award ceremony for the NC winners. Nine local nonprofits each earned $40,000 in recognition of their exceptional achievements.

Read More

Transparency and transformation

Transparency and transformation

We believe in the private sector – and the healthcare industry’s – power to do immense good.  It is inherent in our role discovering, developing, and ensuring access to medicines and vaccines for patients around the world. Often, this good comes from working with others – innovative collaborations in the race to respond to the Ebola outbreak, to develop the world’s first malaria vaccine, and the quest to save one million children’s lives through our global partnership with Save the Children

Read More

The difference between the academy and the company

The difference between the academy and the company

In the November issue of Life Science Leader, Patrick Vallance, leader of GSK Pharmaceuticals R&D, describes his transition from academia to industry and how that shaped his vision for R&D. “If you’d asked me the day before I decided to move to GSK, I would have said I absolutely had no intention of moving to industry,” he recalls.

Read More